Last updated: May 26, 2026
Meprobamate Suppliers: Who Manufactures, Where They Supply, and What to Check in Drug Registration
Meprobamate sourcing is typically handled through branded product owners, contract manufacturers for finished dosage forms (tablets/capsules), and raw-material suppliers for the active pharmaceutical ingredient (API). The supplier universe is best mapped by (1) the branded finished-dose market authorization holder, (2) the U.S. and global API/finished-dose manufacturers listed on product submissions and registrations, and (3) the DMF and manufacturing-site footprint that controls what can be filed, supplied, and used in generic/authorized generic products.
Because no specific country, market (US/EU/UK/Canada/other), or product strength/formulation (tablet vs capsule) is provided, a complete supplier list cannot be generated without producing incomplete or potentially incorrect names.
What companies supply meprobamate API (raw material)
API supply is usually concentrated in chemical manufacturers that produce meprobamate and then sell to finished-dose manufacturers under commercial supply agreements or as permitted under drug master file (DMF) relationships.
What to verify for meprobamate API suppliers
- DMF status and referenceability for finished-dose filing and cross-reference control (U.S. DMF for API, if applicable).
- Manufacturing site (primary control point for regulatory access).
- Impurity profile and specs consistent with pharmacopeial requirements for meprobamate.
- Quality system readiness for downstream audit (GMP status, inspection history).
- Regulatory permissions for intended markets (e.g., US DEA schedule implications where applicable, plus local narcotics controls if enforced by country).
Common supplier types
- API producers selling to multiple finished-dose manufacturers.
- Finished-dose companies that vertically integrate API production for internal supply continuity.
- Trading/distribution firms that repackage or route API under contract supply terms.
Who supplies meprobamate tablets or capsules as finished dosage forms
Finished-dose supply depends on whether the buyer needs:
- Branded product supply from the marketing authorization holder, or
- Generic/authorized generic supply from manufacturers producing to an approved labeling.
What determines finished-dose supplier availability
- The NDC and labeler in the target market.
- Whether the product is marketed as prescription and the distribution channel constraints.
- Whether production is done in-house or via a contract manufacturing organization (CMO).
What to check in the supply chain
- Labeler on the finished product (indicates the marketing authorization holder in the market).
- GMP manufacturing site in product submission records.
- Batch release testing capability and validated analytical methods for meprobamate assay and related substances.
What suppliers are listed on the Orange Book for meprobamate
In the U.S., the Orange Book ties a drug’s NDA/ANDA to the active ingredient, dosage form, and exclusivity/patent linkage. Supplier identification is then derived from:
- Applicant/holder for the NDA/ANDA,
- Manufacturer(s) listed in application materials,
- and product labeler details.
A complete Orange Book-based supplier list requires selecting the specific meprobamate listed product(s) and strengths, which are not provided.
How do you map meprobamate suppliers by DEA and controlled-substance handling
Meprobamate has controlled-substance handling rules that can affect:
- Eligible distributors
- Storage and shipping requirements
- Customer qualification and compliance documentation
Supplier qualification checklist for controlled-substance distribution
- Licensure alignment in the destination jurisdiction.
- Ability to meet inventory, warehousing, and chain-of-custody requirements.
- Documentation for customer onboarding and audits.
- Secure distribution logistics for prescription controlled substances.
What manufacturing and IP barriers affect who can supply meprobamate
Supplier access can be constrained by:
- Limited number of qualified API sources
- Tight DMF access or reference arrangements
- Finished-dose GMP capacity
- Proprietary process controls that require qualification and validation
IP and filing barriers
- If a meprobamate product has listed patents or method-of-manufacture protections, new entrants may be blocked or must wait for expiration or rely on non-infringing pathways.
- Even when patents expire, facility qualification and regulatory changes can gate new supply.
How does meprobamate supply differ across the US, EU, UK, and other markets
Supplier mapping changes by region due to:
- Which companies hold marketing authorizations in each market.
- Local GMP inspection outcomes.
- DMF and dossier referencing practices (particularly in the EU/UK).
- Controlled-substance administrative controls.
Region-specific supplier approach
- US: map NDA/ANDA holders and labelers, then confirm manufacturer sites through submission-linked documentation and current product labeling.
- EU/UK: map marketing authorization holder and responsible manufacturer sites from local registers.
- Other markets: map by importer-of-record and national drug listing databases, then trace manufacturing sites.
Commercial question: Which supplier model is safest for uninterrupted meprobamate supply
For buyers seeking continuity, the lowest risk supply path is typically:
- direct supply from a finished-dose manufacturer (or their approved CMO),
- using an API sourced from a qualified and regulator-referenced production site.
What to demand from prospective meprobamate suppliers
- Written confirmation of GMP status and manufacturing site.
- CoA scope including related substances, residual solvents, and heavy metal specs.
- Batch-level traceability and change control commitments.
- Ability to support regulatory filings (DMF letter of access where required).
Key Takeaways
- Meprobamate supply is controlled by the intersection of API manufacturing qualification, finished-dose GMP capacity, and controlled-substance distribution requirements.
- A true “supplier list” is only defensible when anchored to a specific market and product presentation (country, dosage form, strength, and whether branded or generic).
- Buyers should qualify suppliers by (1) manufacturing site GMP readiness, (2) DMF or dossier accessibility for filings, (3) controlled-substance distribution licensure, and (4) batch-release testing capability.
FAQs
- How do I find meprobamate API suppliers that can support an ANDA filing?
- Which documents prove meprobamate API GMP compliance for contract manufacturers?
- What controlled-substance shipping requirements affect meprobamate distributors?
- How do I identify the finished-dose manufacturer behind a specific meprobamate NDC?
- What supplier risks cause meprobamate backorders (API shortages vs finished-dose capacity)?
References
- FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (U.S. FDA). https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
- U.S. FDA Drug Master File (DMF) information. (U.S. FDA). https://www.fda.gov/drugs/drug-master-files-dmfs
